Pharmacodynamic and Pharmacokinetic Features of Cabergoline

@article{Fariello2012PharmacodynamicAP,
  title={Pharmacodynamic and Pharmacokinetic Features of Cabergoline},
  author={R. Fariello},
  journal={Drugs},
  year={2012},
  volume={55},
  pages={10-16}
}
  • R. Fariello
  • Published 2012
  • Medicine
  • Drugs
  • SummaryThe appearance of late motor complications is the major drawback of long term levodopa therapy in patients with Parkinson’s disease. Although disease progression may be a factor in the aetiology of these complications, unfavourable properties of levodopa may promote their development. These include competition with amino acids for gastrointestinal absorption and passage through the blood-brain barrier; and a short duration of action with a rapid peak plasma concentration and rapid… CONTINUE READING
    5 Citations

    References

    SHOWING 1-10 OF 61 REFERENCES
    Cabergoline in the treatment of early parkinson's disease
    • 118
    A rationale for dopamine agonists as primary therapy for Parkinson's disease.
    • C. Olanow
    • Medicine
    • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
    • 1992
    • 61
    • PDF
    Motor complications associated with chronic levodopa therapy in Parkinson's disease.
    • 150
    Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued
    • 19
    The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    • 511
    Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
    • 129
    Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids.
    • 11
    Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
    • 80